

**Notice of the  
Annual General  
Meeting**

22 June 2022 at 09:00

# NOTICE OF THE MALCOR MEDICAL AID SCHEME ANNUAL GENERAL MEETING

The Board of Trustees of the Malcor Medical Aid Scheme are excited to invite you to our virtual Annual General Meeting via the Zoom Platform.

**Meeting date:** 22 June 2022

**Meeting time:** 09:00

**Registration:** Online registration will open at 09:00 on 07 June 2022

**Venue:** Zoom, virtual meeting (you will receive the meeting link after registration and vetting has been completed)

Please register [here](#) to attend the AGM.

Following successful registration, you will receive an email containing a unique meeting invitation link within a few days.

Members attending the AGM will be required to provide their South African Identity Number/Passport Number, together with their membership number.

This meeting is open to all members in good standing.

We look forward to seeing you at the meeting.

Kind regards

Peter Dorfan

Principal Officer

Malcor Medical Aid Scheme

## ANNUAL GENERAL MEETING MALCOR MEDICAL AID SCHEME

Date:	22 June 2022
Time:	09:00 – 10:00
Venue:	Virtual AGM, via Zoom

## AGENDA

<b>1</b>	<b>Constitution</b>	<b>Chairperson</b>
1.1	Notice of meeting and welcome	
1.2	Present	
1.3	Apologies	
1.4	Confirmation of quorum	
1.5	Confirmation of motions submitted	
<b>2</b>	<b>Minutes of the previous meeting</b>	<b>Chairperson</b>
2.1	Approval of the minutes of the Annual General Meeting held on 24 June 2021	
<b>3</b>	<b>Annual financial statements</b>	<b>Principal Officer</b>
3.1	Approval of the Annual Financial Statements for the year ending 31 December 2021	
<b>4</b>	<b>Appointment of the auditors</b>	<b>Principal Officer</b>
4.1	Harris, Dowden & Fontaine	
<b>5</b>	<b>Appointees to the Board of Trustees</b>	<b>Principal Officer</b>
5.1	Notification of appointees to the Malcor Board of Trustees	
<b>6</b>	<b>Submitted motions</b>	<b>Principal Officer</b>
6.1	To be announced	
<b>7</b>	<b>General</b>	<b>Principal Officer</b>
<b>8</b>	<b>Closure</b>	<b>Chairperson</b>

Any member who is entitled to attend and vote at a general meeting of the Malcor Medical Aid Scheme shall have the right to appoint a proxy, who must be a main member of good standing with the Scheme, to vote in his stead.

A proxy form is enclosed.

Notices of motions to be placed before the Annual General Meeting must reach the Principal Officer at pdorfan@gmail.com by no later than 15 June 2022.

**Note:**

The Malcor Medical Aid Scheme Annual Financial Statements for the year ended 31 December 2021 are available on the Scheme's website or from the Malcor Medical Aid Scheme by calling 0860 100 698. Please log in to [www.malcormedicalaid.co.za](http://www.malcormedicalaid.co.za) to obtain these documents. Alternatively, if you are an employee of an employer group, you may request a copy from your employer contact person.

Included:

- Minutes of the Annual General Meeting held on 24 June 2021
- Proxy form

## MINUTES OF THE 26<sup>TH</sup> ANNUAL GENERAL MEETING OF THE MALCOR MEDICAL AID SCHEME

<b>Date/ time:</b>	Thursday, 24 June 2021 at 08:30
<b>Venue:</b>	Virtual meeting via MS Teams

	<b>Present – Members:</b>	Mr Peter Dorfan Mr Bert Marais Mr Clinton Van Zitters Ms Anele Gqada Ms Antoinette Matthyser Ms Desislava Ivanova Mr Juandre Els Mr Ravi Govender Ms Pascale Bargehr Ms Wendy Scott Mr Warren Gates Mr Rodger Webb Mr Geoff Du Preez Ms Susanna Engelbrecht Mr Daniel Villet Ms Alison Lowes Mr Frank Thayer Ms Naomi Buchner Ms Lynette James Ms Maria du Plessis Ms Monica Coetzee Mr Pieter Swart Ms Cornelia Campher Mr Pieter Swart Ms Dorcas Kulwa Ms Esther Morgan Ms Valerie Hall Mr Denis Nqubuka Mr Joe Morris Mr Riaan Verster	Chairperson
--	---------------------------	--	-------------

	<b>Present - Non-members:</b>	Ms Marlene Wilkinson Ms Margot van Rooyen Mr Andries Katsi Mr Brian Dowden Mr Charles Fontaine Ms Avril Jacobs	Administrator – Fund Manager Administrator – Fund Coordinator Administrator – ICT Operator External Audit Partner External Audit Partner CMS Representative
	<b>Apologies:</b>	Mr C Botha	

## ITEMS MINUTED

1.	CONSTITUTION	ACTION
1.1	<p><b>Notice of meeting and welcome</b></p> <p>The Chairperson of the Scheme, Mr Marais, opened the meeting and welcomed all attendees to the 26th Annual General Meeting ('AGM') of the Scheme. The Chairperson confirmed that the Notice of the Annual General Meeting had been sent to all Members of the Scheme in accordance with the Rules of the Scheme. He extended a special welcome to Ms Avril Jacobs from the Council for Medical Schemes ('CMS'), the external auditors from Harris Dowden and Fontaine and the representatives of the administrator.</p> <p>The Chairperson advised matters for the 2019 and 2020 financial years will be discussed at this AGM due to the postponement of the 2020 AGM because of the COVID-19 pandemic restrictions. It was noted that the Scheme was exempted by the CMS from having an AGM in 2020.</p> <p>Ms Wilkinson presented the meeting etiquette and explained how the voting and approval of items will be conducted during this virtual meeting. Ms. Wilkinson further demonstrated basic functions of the Zoom platform, such as how to raise a hand or comment in the notes section.</p>	
1.2	<p><b>Present</b></p> <p>The Chairperson confirmed the attendance.</p>	
1.3	<p><b>Apologies</b></p> <p>The Chairperson confirmed the apologies tendered.</p>	
1.4	<p><b>Confirmation of quorum</b></p> <p>In terms of Rule 27 of the Scheme Rules, at least 15 members present in person are required to constitute a quorum of the meeting. As this requirement was met, the Chairperson declared the meeting to be duly constituted noting the meeting was virtual in nature and more than 15 members were present on the Zoom meeting.</p> <p>The Chairperson advised that following a directive from the CMS, the number of attendees to constitute a quorum will be changed from 15 to 30 members for 2022. The Chairperson continue to note that the minimum requirements for a quorum at a Special Annual General Meeting is a minimum of 50 member or 1 for every 10 000 members, whichever is the greatest. The Rules of the Scheme will be updated accordingly for the 2022 submission.</p> <p>The Chairperson confirmed that a proxy was submitted by Ms Amanda Criswell to appoint Mr Clinton van Zitters. No other proxy forms were received.</p>	
1.5	<p><b>Confirmation of motions submitted</b></p> <p>The Chairperson advised that no motions had been brought before the Principal Officer or the Board of Trustees to be added to the Agenda of the meeting.</p>	
2.	MINUTES OF THE PREVIOUS MEETING	ACTION
2.1	<p><b>Annual general meeting held on 19 June 2019</b></p> <p>The minutes of the 25th AGM of the Scheme held on 19 June 2019 were proposed for approval by the Chairperson, Mr Riaan Verster supported and Mr Peter Dorfan seconded the proposal. The Chairperson confirmed that he would then sign the minutes as a correct record of the proceedings of that meeting.</p>	
3.	ANNUAL FINANCIAL STATEMENTS	ACTION
3.1	<p><b>Annual Financial Statements for the year ending 31 December 2019</b></p> <p>The Chairperson noted that the Annual Financial Statements of the Scheme for the year ended 31 December 2019, including the report of the trustees, had been distributed with the Notice to the members and made available for inspection via the Scheme's website and at the various pay points.</p>	
3.2	<p><b>Annual Financial Statements for the year ending 31 December 2020</b></p> <p>The Chairperson noted that the annual financial statements of the Scheme for the year ended 31 December 2020, including the report of the trustees, had been distributed with the Notice to the members and made available for inspection via the Scheme's website and at the various pay points.</p> <p>The Chairperson asked if there were any questions relating to the 2019 and 2020 annual financial statements.</p> <p>The Chairperson presented the following Scheme related information:</p>	

## Statement of Financial position

	2020 R'000	2019 R'000
<b>Assets</b>		
<b>Non-current assets</b>	46,491	47,413
Investments at fair value through profit or loss	46,491	47,413
<b>Current assets</b>	106,777	60,549
Trade and other receivables	894	1,613
Cash and cash equivalents	105,883	58,936
<b>Total assets</b>	<b>153,268</b>	<b>107,962</b>
<b>Funds and Liabilities</b>		
Members's Funds	125,114	86,892
<b>Current liabilities</b>	28,154	21,070
Outstanding risk claims provision	6,100	6,900
Trade and other payables	22,054	14,170
<b>Total funds and liabilities</b>	<b>153,268</b>	<b>107,962</b>
<b>Accumulated Funds (per Regulation 29)</b>	<b>125,114</b>	<b>85,296</b>
<b>Solvency</b>	<b>41.71%</b>	<b>30.04%</b>

## Statement of Comprehensive Income

	2020 R'000	2019 R'000
<b>Risk contribution income</b>	299,966	283,917
Healthcare expenditure	(258,356)	(278,027)
<b>Underwriting surplus/(deficit)</b>	41,610	5,890
Admin and other expenses	(15,749)	(15,652)
<b>Operating surplus/(deficit)</b>	25,861	(9,762)
Investment and other income	12,361	14,092
<b>Total comprehensive surplus</b>	<b>38,222</b>	<b>4,330</b>

## Trustee Expenditure

	2020 R'000	2019 R'000
Trustee remuneration	95	59
Trustee reimbursements - travel costs	3	16
<b>Total trustee expenditure</b>	<b>98</b>	<b>75</b>

## Four-year summary

	2020 R'000	2019 R'000	2018 R'000	2017 R'000
Investments held at fair value through profit or loss	46,491	47,413	43,014	42,550
Members funds	125,114	86,892	82,562	73,016
Comprehensive surplus	38,222	4,330	9,546	6,382
Solvency %	41.7%	30.0%	29.9%	25.7%
Claims Ratio	86.1%	97.9%	93.9%	101.2%

No questions were raised and the Chairperson proposed that the 2020 Annual Financial Statements be adopted. This was supported by Ms Ivanova and seconded by Mr Riaan Verster.

## ITEMS MINUTED (CONTINUED)

<b>4.</b>	<b>APPOINTMENT OF THE AUDITORS</b>	<b>ACTION</b>
4.1	<p><b>Harris, Dowden and Fontaine</b></p> <p>The Chairperson noted that in terms of Section 36 of the Medical Schemes Act, auditors must be appointed at each Annual General Meeting to hold office from conclusion of that meeting to the conclusion of the next Annual General Meeting.</p> <p>The Chairperson advised that a recommendation was put forward that the current Scheme auditors, Harris Dowden and Fontaine, be retained to perform the 2021 audit.</p> <p>The reappointment was supported by Mr Peter Dorfan and seconded by Mr Joe Morris.</p>	
<b>5.</b>	<b>SUBMITTED MOTIONS</b>	<b>ACTION</b>
5.1	<p><b>Motions Submitted</b></p> <p>The Chairperson noted that no motions were received for discussion and no motions were raised in the meeting.</p>	
<b>6.</b>	<b>GENERAL</b>	<b>ACTION</b>
6.1	<p><b>General matters for discussion</b></p> <p>The Chairperson opened the floor for any comments or questions. No additional comments or questions were raised.</p>	
<b>7.</b>	<b>CLOSURE</b>	<b>ACTION</b>
	<p>There being no further business, the Chairperson thanked all present for their attendance and declared the meeting closed at 09:24.</p>	

Signed as a true record of proceedings.

---

Chairperson signature

---

Date

MALCOR MEDICAL AID SCHEME

Registration number: 330

Reference number: 1547

ANNUAL FINANCIAL STATEMENTS

**FOR THE YEAR ENDED 31 DECEMBER 2021**

## **MALCOR MEDICAL AID SCHEME**

### **ANNUAL FINANCIAL STATEMENTS**

for the year ended 31 December 2021

	<b>Page</b>
Statement of responsibility by the board of trustees	9
Statement of corporate governance by the board of trustees	10
Report of the board of trustees	11 – 22
Report of the independent auditors	23 – 26
Statement of financial position	27
Statement of comprehensive income	28
Statement of changes in funds and reserves	29
Statement of cash flows	30
Notes to the annual financial statements	31 – 64



## MALCOR MEDICAL AID SCHEME

### ANNUAL FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### STATEMENT OF RESPONSIBILITY BY THE BOARD OF TRUSTEES

The trustees are responsible for the preparation, integrity and fair presentation of the annual financial statements of Malcor Medical Aid Scheme ("the Scheme") which have been prepared in accordance with International Financial Reporting Standards (IFRS) and the requirements of the Medical Schemes Act of South Africa. In addition, the trustees are responsible for preparing the report of the board of trustees.

The trustees:-

- consider that in preparing the annual financial statements they have used the most appropriate accounting policies, consistently applied and supported by reasonable and prudent judgements and estimates;
- are satisfied that the information contained in the annual financial statements fairly presents the results of operations and cash flows for the year and the financial position of the Scheme at year-end.
- are responsible for ensuring that adequate accounting records are kept. The accounting records disclose with reasonable accuracy the financial position of the Scheme to enable the trustees to ensure that the annual financial statements comply with the relevant legislation;
- are responsible for such internal controls as the trustees determine are necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and for maintaining an effective system of risk management.

The Scheme operates in a well-established control environment, which is well documented and regularly reviewed. This incorporates risk management and internal control procedures, which are designed to provide reasonable, but not absolute, assurance that assets are safeguarded and the risks facing the business are being controlled.

The going concern basis has been adopted in preparing the annual financial statements. The trustees have no reason to believe that the Scheme will not be a going concern in the foreseeable future, based on forecasts and available cash resources. These financial statements support the viability of the Scheme.

The Scheme's external auditors, Harris Dowden & Fontaine, are responsible for auditing the annual financial statements and their report is presented on page 16.

Harris Dowden & Fontaine have unrestricted access to all financial records and related data, including minutes of all meetings of members, the trustees and the Audit and Risk Committee. The trustees believe that all their representations made to the independent auditors during their audit were accurate and appropriate.

The annual financial statements were approved by the board of trustees on 21 April 2022 and are signed on its behalf by:



A MARAIS  
Chairman



A LOWES  
Trustee



P DORFAN  
Principal officer

## **MALCOR MEDICAL AID SCHEME**

### **ANNUAL FINANCIAL STATEMENTS**

for the year ended 31 December 2021

#### **STATEMENT OF CORPORATE GOVERNANCE BY THE BOARD OF TRUSTEES**

The Malcor Medical Aid Scheme is committed to the principles and practice of fairness, responsibility, transparency and accountability in all dealings with its stakeholders. The Scheme complies with a recognised governance framework and conducts its affairs according to ethical values. The trustees are proposed and elected by the members of the Scheme.

The board of trustees view good governance not only as complying with legislative provisions and applying the relevant principles of King on corporate governance, but view it as integral to the success, sustainability and financial soundness of the Malcor Medical Scheme. The trustees are satisfied that the Scheme has in all material respects complied with the provisions and spirit of its rules, the Medical Schemes Act 131 of 1998, as amended and its regulations, other than those matters noted in the Board of Trustees report.

#### **BOARD OF TRUSTEES**

The board of trustees meets regularly and monitors the performance of the administrator and other service providers. They address a range of key issues and ensure discussion of items of policy, strategy and performance are informed and constructive.

All trustees have access to the advice and services of the principal officer and, where appropriate, may seek independent professional advice at the cost of the Scheme.

#### **RISK MANAGEMENT AND INTERNAL CONTROL**

The trustees are accountable for the process of risk management and internal controls. Risks are reviewed and identified on an ongoing basis and appropriate strategies are implemented and monitored.

The trustees have established an Audit and Risk Committee ("ARC") mandated under terms of reference to oversee all risk and corporate governance issues pertaining to the Scheme in accordance with accepted corporate governance practices.

The administrators of the Scheme maintain internal controls and systems designed to provide reasonable assurance as to the integrity and reliability of the financial statements and to safeguard, verify and maintain accountability for its assets adequately. Such controls are based on established policies and procedures and are implemented by trained personnel with the appropriate segregation of duties.

No event or item has come to the attention of the board of trustees that indicates any material breakdown in the functioning of the key controls and systems during the year under review.

#### **PERFORMANCE MONITORING OF BUDGETS**

The budget for the Scheme is set annually and approved by the trustees. The performance against budget is monitored monthly by the trustees and agreed remedial actions are implemented.

#### **PERFORMANCE MONITORING OF TERMS OF REFERENCE**

The trustees approve the terms of reference of the ARC and monitor its performance against it.



A MARAIS  
Chairman



A LOWES  
Trustee



P DORFAN  
Principal Officer

21 April 2022

## MALCOR MEDICAL AID SCHEME

### ANNUAL REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2021

The board of trustees ("the Board") hereby presents its report for the year ended 31 December 2021.

#### 1. DESCRIPTION OF THE MEDICAL SCHEME

##### 1.1. Terms of registration

The Malcor Medical Aid Scheme ("the Scheme") is a restricted membership scheme registered in terms of the Medical Schemes Act No 131 of 1998 ("the Act").

The Scheme operates for the benefit of its members and its trustees oversee and govern the business of the Scheme on behalf of its members.

##### 1.2. Benefit options with Malcor Medical Aid Scheme

The Scheme offered 4 benefit options to its members during the year - Plans A, B, C and D.

Plans A, B and C are graded non-savings benefit options, while Plan D is a low-cost benefit option serviced by National HealthCare Group (Pty) Ltd ("National HealthCare"). National HealthCare has in return for a capitation fee, assumed the risk of providing the Plan D members with the medical benefits permitted by the Plan.

#### 2. SCHEME MANAGEMENT AND THIRD PARTY SERVICE PROVIDERS

##### 2.1 Board of trustees

The trustees are all elected by the members. Elections are held every three years and the most recent election was held during the 2019 financial year. The next election will be held during the 2022 financial year.

The Board are also entitled in terms of the Scheme rules to appoint a trustee to fill a vacancy during the financial year to hold office until the next annual general meeting.

The board of trustees during the year under review and at the date of this report were:

<u>Name</u>	<u>Number of meetings attended during the year</u>	
	<u>A</u>	<u>B</u>
A Marais (Chairman)	5	5
J Els	3	5
L James	5	5
A Lowes	5	5
C Botha (Resigned 29 September 2021)	4	5
W Scott	4	5
C Van Zitters	5	5
R Verster	5	5
R Govender	5	5
P Dorfan (Principal Officer)	5	5

A - Actual number of meetings attended

B - Total possible meetings

There were 5 trustee meetings held during the year under review and none of the trustees, other than the chairperson received remuneration relating to such services. The chairperson received remuneration of R96,371 (2020: R95,000) for his services to the Scheme during the year.

**MALCOR MEDICAL AID SCHEME**

**ANNUAL REPORT OF THE BOARD OF TRUSTEES**  
for the year ended 31 December 2021

**2. SCHEME MANAGEMENT AND THIRD PARTY SERVICE PROVIDERS (continued)**

**2.2. Principal officer**

P Dorfan

16 Jersey Drive  
Longmeadow Business Estate East  
Edenvale

P O Box 8012  
Greenstone  
1616

The principal officer received remuneration of R677,981 (2020: R696,813) for his services to the Scheme during the year.

**2.3. Registered office and postal address of the Scheme**

Discovery Health Head Office  
1 Discovery Place  
Sandton

P O Box 786722  
Sandton  
2146

**2.4. Scheme administrator**

Discovery Health (Pty) Ltd  
Accreditation number: 19  
Discovery Health Head Office  
1 Discovery Place  
Sandton

P O Box 786722  
Sandton  
2146

**2.5. Managed care administrators**

Discovery Health (Pty) Ltd  
Managed care accreditation number: 6  
Discovery Health Head Office  
1 Discovery Place  
Sandton

P O Box 786722  
Sandton  
2146

National HealthCare Group (Pty) Ltd  
Managed care accreditation number: 22  
Route 21 Corporate Park  
72 Regency Drive  
Irene

P O Box 11480  
Queenswood  
0121

**2.6. Investment advisors**

P Rigby  
Financial service provider number: 1177  
Alexander Forbes Financial Services (Pty) Ltd  
115 West Street  
Sandown  
(Termination date: 31 January 2021)

P O Box 785451  
Sandton  
2146

G Webb  
Financial service provider number: 873  
Sygnia Asset Management (Pty) Ltd  
Katherine & West Building, West Street  
Sandton  
2196  
(Appointment date: 1 February 2021)

7th Floor, The Foundry  
Green Point  
Cape Town  
8001

**MALCOR MEDICAL AID SCHEME**

**ANNUAL REPORT OF THE BOARD OF TRUSTEES**  
for the year ended 31 December 2021

**2. SCHEME MANAGEMENT AND THIRD PARTY SERVICE PROVIDERS (continued)**

**2.7. Auditors**

Harris Dowden & Fontaine  
IRBA registration number: 943703  
7 Pam Road  
Morningside  
Sandton

P O Box 651129  
Benmore  
2010

**2.8. Scheme committees**

In accordance with good corporate governance and the provisions of the Act, the Scheme has an Audit and Risk Committee ("ARC"). The ARC is appointed by the trustees and mandated by them by means of written terms of reference as to its membership, authority and duties. The ARC is required to have a minimum of five members the majority of whom, including the chairman, are not officers of the Scheme or its administrator.

The primary responsibility of the members of the ARC is to assist the board of trustees in carrying out its duty relating to the Scheme's accounting policies, internal control systems, financial reporting and corporate governance practices and risk management. The external and internal auditors formally report to the ARC on the critical findings arising from their audits.

The trustees monitor the performance of the ARC against its related terms of reference. No deficiencies were noted for the 2021 financial year.

The ARC in turn, make recommendations to the trustees arising from their abovementioned duties.

The ARC members during the year under review and at date of this report were:

<u>Name</u>	<u>Number of meetings</u>	
	<u>A</u>	<u>B</u>
Independent members:		
G Kapp (Chairperson)	3	3
J Englund	3	3
E Toerien	1	3
M Lorgat	2	3
Trustee members:		
A Lowes	3	3
J Els	3	3
Principal Officer:		
P Dorfan	3	3

A - Actual number of meetings attended  
B - Total possible meetings

## MALCOR MEDICAL AID SCHEME

### ANNUAL REPORT OF THE BOARD OF TRUSTEES for the year ended 31 December 2021

## 2. SCHEME MANAGEMENT AND THIRD PARTY SERVICE PROVIDERS (continued)

### 2.8. Scheme committees (continued)

The principal officer of the Scheme and representatives of the administrators as well as the internal and external auditors are invited to attend all ARC meetings and have unrestricted access to the chairperson of the committee.

There were 3 ARC meetings held during the year under review and none of the ARC members, with the exception of the ARC chairperson, received any remuneration or was reimbursed for any expenditure relating to such services.

The chairperson received remuneration of R45,365 (2020: R56,750) for his services to the Scheme during the year.

The ARC reported that:

- It carried out its duties in terms of the Act and its terms of reference approved by the Board.
- The external auditors have confirmed their independence.
- The combined assurance provided by management and the external and internal auditors has led them to conclude that the internal controls of the Scheme are adequate and effective.
- It has reviewed the Scheme's annual financial statements and accounting policies, obtained assurance from the external auditors in this regard and recommended the adoption of the annual financial statements by the Board for presentation to members.

## 3. MANAGEMENT OF RISK

### 3.1. Commercial reinsurance

Since inception of the Scheme the trustees have believed it is in the best interest of the members to have a stop-loss reinsurance cover to protect the Scheme from significant losses.

Prior to the 2013 financial year, the trustees arranged for the Scheme to have this cover with the approval of the Council for Medical Schemes ("Council"). The Scheme was then responsible for the related reinsurance premiums and was entitled to the proceeds of the related claims.

With effect from 1 January 2013, the individual employer groups elected to arrange for the stop-loss reinsurance to be entered into by the respective employers of the Scheme's members. Although the reinsurance premiums are borne by such employers, they have undertaken to continue to provide the Scheme with the benefit of any related reinsurance claims by paying such amounts into the Scheme by way of additional funding.

### 3.2 Risk transfer arrangements

National HealthCare Group (Pty) Ltd provides Plan D members with the medical benefits attributable to the Plan in return for a capitation fee. This is disclosed in the current annual financial statements and is the only risk transfer arrangement.

## MALCOR MEDICAL AID SCHEME

### ANNUAL REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2021

#### 3. MANAGEMENT OF RISK (Continued)

##### 3.3. Investment strategy

The Scheme's investment strategy is to ensure there is a sum equivalent to at least two month's expected claims and administration costs in the Scheme's bank accounts and that the investments comply with the regulations of the Act. Within this overall strategy the objective is to invest no more than 40% in equities, 100% in cash or bonds and 5% in property holding investments. The Scheme adhered to the investment strategy and at year end had invested 19.22% (2020: 19.73%) of the Scheme's funds available for investment in equities, 76.57% (2020: 79.73%) in cash or bonds and 0.48% (2020: 0.54%) in equities in property holding investments. The return achieved on available-for-sale investments as a percentage of the weighted average fair value per month for the year under review was 6.7% (2020: -4.82%).

All investments are in the name of the Scheme and no withdrawal or investment changes are permitted without the approval of the trustees and the written approval of the principal officer.

The trustees of the Scheme review the allocation and performance of investments on a quarterly basis to monitor the returns and ensure compliance with the Act and review the investment policy on an annual basis. Advice in respect of specific funds in which the Scheme is invested is taken from the Scheme's investment advisor and professional asset consultants. The Scheme has elected an investment sub-committee during the current year.

The investment sub-committee members during the year under review and at date of this report were:

<u>Name</u>	<u>Number of meetings</u>	
	<u>A</u>	<u>B</u>
A Marais (Chairman)	2	2
R Verster	2	2
P Dorfan (PO)	2	2
C Botha	1	2

A - Actual number of meetings attended

B - Total possible meetings

Details of investments are set out in the annual financial statements.

## MALCOR MEDICAL AID SCHEME

### ANNUAL REPORT OF THE BOARD OF TRUSTEES for the year ended 31 December 2021

#### 3. MANAGEMENT OF RISK (Continued)

##### 3.4 Management of Insurance risk

The primary insurance activity carried out by the Scheme assumes the risk of loss incurred by members and their dependants relating to medical care. These risks relate to the health of the Scheme members. As such the Scheme is exposed to the uncertainty surrounding the timing and severity of medical claims made by its members.

The Scheme manages its insurance risk through benefit limits and sub-limits, approval procedures for transactions that involve pricing guidelines, pre-authorisation and case management, service provider profiling, centralised management of the risk transfer arrangement, as well as the monitoring of emerging issues, and, as detailed under 3.1 above, by stop-loss reinsurance cover.

The Scheme uses several methods to assess and monitor insurance risk exposures for both individual types of risks insured and overall risks. The principal risk is that the frequency and severity of claims are greater than expected.

An assessment of the major risks affecting the Scheme and the most effective manner in which these risks may be mitigated is considered by the ARC and the Board on a regular basis.

Insurance events are, by their nature, random, and the actual number and size of events during any one year may vary from those estimated using established statistical techniques. There were no changes to assumptions used to measure insurance assets and liabilities that have a material effect on the annual financial statements and there were no terms and conditions of insurance contracts that have a material effect on the amount, timing and uncertainty of the Scheme's cash flows.

##### 3.5. COVID-19

During 2020 and up to 22 March 2022, 2,437 beneficiaries of Malcor Medical Aid Scheme members tested positive for COVID-19, 2,373 beneficiaries recovered and 41 beneficiaries passed away. The Scheme's COVID-19 related claims costs (i.e. costs for tests, consultations, medicine and hospitalisation) was approximately R41.59m up to 22 March 2022 (14.00% of risk contributions).

The Trustees have monitored the impact of the COVID-19 pandemic on the Scheme closely during 2021. The Trustees were provided with regular updates in respect of the COVID-19 pandemic regarding emerging trends in the country in general as well as within the medical industry and for the Scheme.

Claims costs in 2021 were slightly lower than budget as was the case in 2020, following the further cancellation and/or postponement of elective surgeries as well as a general reduction in the utilisation of other medical services. Although the Scheme experienced a lower than anticipated claims experience for 2021, the claims ratio has increased from 86.13% at the end of 2020 to 94.69% in 2021 in response to shorter and less strict lockdown restrictions than 2020. This resulted in a gross healthcare surplus of R 15.61m for 2021 with the solvency ratio increasing to 45.87%.

It should be noted that it is still expected that there will be a catch up of some of the services during the course of 2022. Some of the surpluses generated in 2021 will therefore be required to fund the catch-up of claims in future. The timing and extent of the catch-up is uncertain at this stage since this will be impacted by potential future waves of COVID infections.

##### *Provision for COVID vaccinations*

COVID-19 vaccination data, recently received from the Department of Health from the EVDS system, showed that a significant number of members had been vaccinated for COVID-19 at public vaccination sites but that a significant portion of cost at these sites have not yet been billed to the Scheme. Therefore, an additional IBNR allowance should be made in for these COVID-19 vaccine costs. The IBNR amount was determined based on the number of doses received by members to date that have not yet been billed multiplied by the assumed cost for each dose (including both the vaccine and administration components).





## MALCOR MEDICAL AID SCHEME

### REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2021

#### 5. REVIEW OF RESULTS FOR THE YEAR

##### 5.1. Results of operations

The results of the operations of the Scheme are set out in the annual financial statements, and the trustees believe that no further clarification is necessary.

##### 5.2. Operational statistics for the Scheme

	2021 R'000	2020 R'000
Amount paid to administrators		
- Administration fee (Note 10 to the annual financial statements)	11,450	11,594
- Managed care fee (Note 9 to the annual financial statements)	6,038	6,124
Total	<u>17,489</u>	<u>17,718</u>

##### 5.3. Accumulated funds ratio

The accumulated funds ratio is calculated as follows:

Total members' funds per statement of financial position	146,424	125,114
Less: Cumulative fair value gain on investments	<u>(10,152)</u>	<u>-</u>
Accumulated funds per Regulation 29	<u>136,271</u>	<u>125,114</u>
Risk contributions	<u>297,072</u>	<u>299,966</u>
Accumulated funds ratio (accumulated funds/risk annual contribution income x 100)	<u>45.87%</u>	<u>41.71%</u>

##### 5.4. Reserve accounts

Movement in the reserve is set out in the statement of changes in funds and reserve. Other than the impact of COVID-19, there have been no unusual movements that the trustees believe should be brought to the attention of members of the Scheme.

##### 5.5. Outstanding risk claims provision

The basis of calculation of the outstanding risk claims provision and the movement in the provision are set out in Note 5 to the annual financial statements. Other than noted in part 3.5 of this report relating to the provision for COVID-19 vaccinations, the basis of calculation is consistent with the prior year and there have been no unusual movements that the trustees believe should be brought to the attention of the members of the Scheme.

##### 5.6. Other

It is evident from the operational statistics set out in note 4 to this report that, ignoring Plan D for which the operating responsibility is outsourced to National HealthCare Group (Pty) Ltd, the average net relevant healthcare expenditure per beneficiary per month reflects an increase of 9% for Plan A, an increase of 18% for Plan B and a increase of 31% for Plan C. This is more than initially expected in view of the generally better tariffs that were negotiated for the Scheme by Discovery Health for 2021.

## **MALCOR MEDICAL AID SCHEME**

### **REPORT OF THE BOARD OF TRUSTEES**

for the year ended 31 December 2021

#### **6. INVESTMENTS IN AND LOANS TO EMPLOYERS OF MEMBERS OF THE SCHEME AND TO OTHER RELATED PARTIES**

With the exception of the indirect investments in Aspen Pharmacare Holdings Limited and Discovery Holdings Limited detailed in paragraph 12(2) below, the Scheme did not hold shares in any related party or in companies whose employees are members of the Scheme.

#### **7. RELATED PARTY TRANSACTIONS**

Related party transactions are set out in Note 16 to the annual financial statements.

#### **8. ACTUARIAL SERVICES**

The Scheme's actuary was consulted in the determination of the contributions and benefit levels.

#### **9. FIDELITY AND PROFESSIONAL INDEMNITY INSURANCE**

In terms of section 33(3) of the Medical Schemes Act, Camargue Underwriting Managers Proprietary Limited, underwritten by Bryte Insurance Company Ltd, Compass Insurance Company Ltd and Lloyds Bank Of London Ltd, has provided professional indemnity and fidelity insurance of R25 million (2020: R25 million) to the Scheme.

#### **10. INTERNAL AUDIT**

Discovery Health Internal Audit provided the ARC with an annual internal audit plan for discussion, regular feedback on their findings, suggested improvements on internal controls as well as feedback on the progress of the audits against the approved audit plan. The external auditors also liaised with Discovery Health Internal Audit to ensure they could minimise their audit procedures in the areas covered by Discovery Health Internal Audit.

#### **11. EVENTS AFTER THE REPORTING DATE**

There were no other events after the reporting date that had a material impact on the Scheme.

## **MALCOR MEDICAL AID SCHEME**

### **REPORT OF THE BOARD OF TRUSTEES**

for the year ended 31 December 2021

#### **12. AREAS OF NON COMPLIANCE WITH MEDICAL SCHEME LEGISLATION FOR THE YEAR UNDER REVIEW**

Although they may not be material in amount or effect, the trustees are required by the Council for Medical Schemes to report on all matters of non-compliance with the Act irrespective of whether or not the external auditors consider the non-compliance as material. In accordance with this requirement, the trustees note:

##### **12.1. Late payment of contributions**

###### **Nature and impact**

In terms of Section 26(7) of the Act, contributions should be received in accordance with the rules of the Scheme. In terms of the Scheme rules, contributions are required to be received no later than three days after their due date. During the financial year certain contributions were identified that were not paid to the Scheme within this deadline period.

###### **Causes of failure**

The failure was mainly caused due to administrative delays by certain participating employers in paying over their respective contributions to the Scheme.

###### **Corrective action**

Whilst every effort is made through credit control procedures to enforce this requirement, the onus is on the member/employer group to ensure compliance. The loss of interest to the Scheme from this delay is minimal.

##### **12.2. Investments in participating employers and medical scheme administrators**

###### **Nature and impact**

Section 35(8)(a), (c) and (d) of the Act states that a medical scheme shall not invest any of its assets in participating employers, medical scheme administrators or persons associated with these organisations. During the year the Scheme did have investments in certain of these organisations.

###### **Causes of failure**

The Scheme invests in investment vehicles which allow investment managers discretion to invest in organisations of their choice. Certain of these choices have resulted in the Scheme having investments in organisations which are in conflict with this Section of the Act.

###### **Corrective action**

The Scheme has received exemption from the provisions of this Section from Council on the grounds that the investments are made, without reference to the Scheme, by the asset managers in the portfolios in which the Scheme invests. These investment choices are therefore not influenced by the Scheme.

## **MALCOR MEDICAL AID SCHEME**

### **REPORT OF THE BOARD OF TRUSTEES**

for the year ended 31 December 2021

#### **12. AREAS OF NON COMPLIANCE WITH MEDICAL SCHEME LEGISLATION FOR THE YEAR UNDER REVIEW (continued)**

##### **12.3. Sustainability of benefit options**

###### **Nature and impact**

In terms of section 33(2) of the Act, each benefit option shall be self-supporting in terms of membership and financial performance. At 31 December 2021 one of the four benefit options incurred deficits as set out in note 14 to the annual financial statements.

###### **Causes of failure**

Plan A was deliberately costed to incur a deficit as the increase in contributions necessary to achieve a surplus would have been too onerous for members on this plan and might lead to members changing to other plans to the detriment of the Scheme as a whole.

###### **Corrective action**

The Trustees are expecting this trend for Plan A to continue in future. The performance of all benefit options is monitored on a continuous basis with a view to improving their financial outcomes, and the Scheme continually evaluates different strategies to address the deficit in these benefit options.

When structuring benefit options, the financial sustainability of all the benefit options is considered. The different financial positions reflect the different disease burdens in each benefit option, among many other factors. The Scheme's strategy on the sustainability of benefit options has to balance short and long-term financial considerations, fairness to both healthy and sick members, and continued affordability of cover for members with different levels of income and healthcare needs. While the Scheme is committed to complying wherever possible with the applicable legislation, it also focuses intensively on the overall stability and financial position of the Scheme as a whole and not only individual benefit options.

In addition, the Scheme continually provides the Registrar with updates on both the Scheme and individual benefit option performance through the monthly management accounts and quarterly monitoring meetings.

## **MALCOR MEDICAL AID SCHEME**

### **REPORT OF THE BOARD OF TRUSTEES**

for the year ended 31 December 2021

#### **12. AREAS OF NON COMPLIANCE WITH MEDICAL SCHEME LEGISLATION FOR THE YEAR UNDER REVIEW (continued)**

##### **12.4. Late payment of claims**

###### **Nature and impact**


Section 59(2) of the Act requires that medical schemes shall pay a member or a supplier of service, any benefit owing to that member or supplier of service within 30 days after the day on which the claim in respect of such benefit was received by the medical scheme.

###### **Causes of failure**

Late payment of claims usually resulted from members or providers submitting claims without the necessary details for these payments to be made timeously. These are isolated cases and thus do not have a material effect on the Scheme.

###### **Corrective action**

The necessary assistance is provided to the identified members and healthcare providers to ensure that these types of isolated cases are minimised.



## **Independent Auditor's Report**

To the Members of Malcor Medical Aid Scheme

### **Report on the audit of the Financial Statements For the year ended 31 December 2021**

#### ***Opinion***

We have audited the financial statements of Malcor Medical Aid Scheme (the Scheme), set out on pages 21 to 56, which comprise the statement of financial position as at 31 December 2021 and the statement of comprehensive income, the statement of changes in members' funds and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, these financial statements present fairly, in all material respects, the financial position of Malcor Medical Aid Scheme as at 31 December 2021 and its financial performance and cash flows for the year then ended in accordance with International Financial Reporting Standards and the requirements of the Medical Schemes Act of South Africa.

#### ***Basis for Opinion***

We conducted our audit in accordance with International Standards on Auditing (ISA's). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Scheme in accordance with the Independent Regulatory Board for Auditors Code of Professional Conduct for Registered Auditors (IRBA Code) and other independence requirements applicable to performing audits of financial statements in South Africa. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical requirements applicable to performing audits in South Africa. The IRBA Code is consistent with the International Ethics Standards Board for Accountants Code of Ethics for Professional Accountants (Parts A and B). We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### ***Key Audit Matters***

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements for the current year. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

##### **1. Outstanding claims provision:**

International Financial Reporting Standards (IFRS) requires the scheme to make provision for all future cash outflows for which a past event has occurred.

As disclosed in Note 5 to the annual financial statements, the carrying amount of the Outstanding Claims Provision ("IBNR") at year end was R 5,750,000. The determination of the IBNR requires the Scheme's Trustees to make assumptions and significant judgement in the valuation thereof, which is determined with reference to an estimation of the ultimate cost of settling all claims incurred but not yet reported at the Statement of Financial Position date.

## **Key Audit Matters (continued)**

How the matter was addressed in the audit:

In evaluating the valuation of the IBNR, we audited the calculations approved by the Board of Trustees and performed various procedures including the following:

- Testing the Scheme's controls relating to the preparation of the IBNR calculation;
- Testing the integrity of the information used in the calculation of the IBNR by performing substantive procedures, on a sample basis, on the completeness and accuracy of the claims data used in calculating the IBNR;
- Performance of an independent estimate of the IBNR using substantive analytical procedures that involved historical claims data and trends and comparing the estimate to the Scheme's IBNR;
- Performance of tests of details on the current year IBNR including testing actual claims experienced subsequent to year end and to as close as possible to audit completion date; and
- Performance of a retrospective review of the IBNR raised in the 2020 financial year based on actual claims paid in 2021 to verify the assumptions applied to determine the IBNR are reasonable.

The assumptions applied in the IBNR are appropriate and we are satisfied that the movement of the IBNR in the Statement of Comprehensive Income and the related disclosure of the IBNR balance, in the Statement of Financial Position and assumptions are appropriate.

We engage with management around the rationale for any adjustments or decisions over and above the numeric calculation.

### **2. Claims and contributions:**

Claims and contributions are significant classes of transactions in the annual financial statements of the scheme. These are also subject to significant risk of fraud or material misstatement. The scheme places significant reliance on the system of internal controls and various analytical and system based checks to ensure that all claims and contributions are valid and accurate.

How the matter was addressed in the audit:

During the audit the claims system is subjected to various tests of controls and exception reports are reviewed.

### **3. Risk Transfer Arrangement:**

The Scheme has entered into a risk transfer arrangement with National Healthcare Group Proprietary Limited (formerly Enabled Proprietary Limited) ("the Capitor") for the duration of the year, which obliges the Capitor to compensate providers for costs incurred by members of the scheme, in the case that an insured event occurred.

How the matter was addressed in the audit:

We tested the accuracy of the risk transfer arrangement fees expense, by agreeing the number of members and rates applied in the calculations, to member records and the service level agreement with the Capitor. No inconsistencies were noted.



### ***Information other than the financial statements***

The Scheme's trustees are responsible for information other than the financial statements which comprises the Statement of Responsibility by the Board of Trustees, and the Report of the Board of Trustees. This other information does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover this other information and we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### ***Responsibilities of the Scheme's Trustees for the Financial Statements***

The Scheme's trustees are responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards and the requirements of the Medical Schemes Act, and for such internal control as the Scheme's trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Scheme's trustees are responsible for assessing the Scheme's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Scheme's trustees either intend to liquidate the Scheme or to cease operations, or have no realistic alternative but to do so.

### ***Auditor's Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an audit report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISA's will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISA's, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Scheme's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Scheme's trustees.

- Conclude on the appropriateness of the Scheme's trustees' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Scheme's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Scheme to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Scheme's trustees regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Scheme's Trustees with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the Scheme's trustees, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### **Report on Other Legal and Regulatory Requirements**

##### *Audit Tenure*

In terms of the Independent Regulatory Board for Auditors (IRBA) Rule published in Government Gazette Number 39475 dated 04 December 2015, we report that we have been the auditor of Malcor Medical Aid Scheme for 13 years.

##### *Non-compliance with the Medical Schemes Act of South Africa*

As required by the Council for Medical Schemes, we report that there are no material instances of non-compliance with the requirements of the Medical Schemes Act of South Africa, that have come to our attention during the course of our audit.

  
HARRIS DOWDEN & FONTAINE  
Registered Auditors  
Per: B.J. DOWDEN

Sandton  
21 April 2022

## MALCOR MEDICAL AID SCHEME

### STATEMENT OF FINANCIAL POSITION

as at 31 December 2021

	Notes	2021 R'000	2020 R'000
<b>ASSETS</b>			
Non-current assets		109,975	46,491
Investments held at fair value through profit or loss	2	109,975	46,491
Current assets		62,971	106,777
Trade and other receivables	3	633	894
Cash and cash equivalents	4	62,338	105,883
<b>Total assets</b>		<b>172,946</b>	<b>153,268</b>
<b>FUNDS AND LIABILITIES</b>			
Members' funds		146,424	125,114
Current liabilities		26,522	28,154
Outstanding risk claims provision	5	5,750	6,100
Trade and other payables	6	20,772	22,054
<b>Total funds and liabilities</b>		<b>172,946</b>	<b>153,268</b>

## MALCOR MEDICAL AID SCHEME

### STATEMENT OF COMPREHENSIVE INCOME

for the year ended 31 December 2021

	Notes	2021 R'000	2020 R'000
<b>Risk contribution income</b>		<b>297,072</b>	<b>299,966</b>
<b>Relevant healthcare expenditure</b>		<b>(281,310)</b>	<b>(258,356)</b>
Net claims incurred		(275,352)	(252,108)
Risk claims incurred	7	(276,281)	(252,938)
Third party claim recoveries		929	830
Net income/(expense) on risk transfer arrangements	8	80	(125)
Risk transfer arrangement fees paid		(2,901)	(2,529)
Recoveries from risk transfer arrangements		2,981	2,404
Managed care: management services	9	(6,038)	(6,123)
<b>Gross healthcare result</b>		<b>15,762</b>	<b>41,610</b>
Administration fees	10	(11,450)	(11,594)
Other administration expenses	11	(3,503)	(3,521)
Broker service fees		(796)	(641)
Net impairment (losses)/gains	12	(64)	5
<b>Net healthcare result</b>		<b>(51)</b>	<b>25,861</b>
Other income		21,912	12,676
Investment income	13	16,367	3,284
Employer group reinsurance recoveries		5,519	9,389
Sundry income		26	3
Other expenditure		(551)	(315)
Asset management fees	2	(551)	(315)
<b>Total net comprehensive income for the year</b>		<b>21,310</b>	<b>38,222</b>

## MALCOR MEDICAL AID SCHEME

### STATEMENT OF CHANGES IN FUNDS AND RESERVES

for the year ended 31 December 2021

	Note	Total
		R'000
<b>Balance as at 1 January 2020</b>		<b>86,892</b>
Total net comprehensive income for the year		38,222
<b>Balance as at 31 December 2020</b>		<b>125,114</b>
Total net comprehensive income for the year		21,310
<b>Balance as at 31 December 2021</b>		<b>146,424</b>

**MALCOR MEDICAL AID SCHEME****RESTATED STATEMENT OF CASH FLOWS**

for the year ended 31 December 2021

	Notes	2021 R'000	2020 R'000
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Cash receipts from members and providers		295,968	301,007
• Cash receipts from members - contributions		296,076	299,882
• Cash receipts from members and providers – other		(108)	1,125
Cash paid to providers, employees and members		(298,097)	(268,389)
• Cash paid to providers and members – claims		(281,326)	(251,879)
• Cash paid to providers and employees – non-healthcare expenditure		(16,771)	(16,510)
Sundry income		5,545	9,392
<b>NET CASH FLOWS FROM OPERATING ACTIVITIES</b>		<b>3,416</b>	<b>42,010</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Purchase of investments	2	(100,219)	(2,022)
Proceeds on disposal of investments held at fair value through profit or loss	2	47,972	262
Investment income	12	5,286	6,697
<b>NET CASH FLOWS FROM INVESTING ACTIVITIES</b>		<b>(46,961)</b>	<b>4,937</b>
<b>NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS</b>		<b>(43,545)</b>	<b>46,947</b>
Cash and cash equivalents at the beginning of the year		105,883	58,936
<b>CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR</b>		<b>62,338</b>	<b>105,883</b>

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 1. PRINCIPAL ACCOUNTING POLICIES

The following are the principal accounting policies applied in the preparation of these financial statements which are consistent with those of the previous year except for the adoption of the standards, amendments and interpretations in note 1.1.1.

##### 1.1 Basis of preparation

The annual financial statements are prepared in South African Rands in accordance with International Financial Reporting Standards ("IFRS") and the requirements of the Medical Schemes Act 131 of 1998, as amended, on a going concern basis using the historical cost basis except as stated below.

The preparation of annual financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Scheme's accounting policies. The notes to the annual financial statements set out those areas involving a high degree of judgement or complexity, or areas where assumptions and estimates are significant to the Scheme's financial statements.

##### Change in accounting policy relating to the format of the Statement of Cash Flows

During 2021 the Council for Medical Schemes (CMS) published Circular 52 of 2021: Statement of Cash Flows. In the circular it was noted that Paragraph 19 of IAS 7 encourages entities to report cash flows from operating activities using the direct method. The Council for Medical Schemes (CMS) introduced the direct method in its 2011 annual statutory returns.

The Statement of Cash Flows (SOCF) has been aligned to the prescribed format as set out in Circular 52 of 2021, with the most notable changes being the reporting of cash flows from operating activities using the direct method. The cash flows from operating activities were previously reported using the indirect method.

This change in accounting policy will be applied in preparing the Financial Statements for the year ended 31 December 2021. The change was applied retrospectively, with the comparative period presented as if this accounting policy had always been applied. Note 23 sets out the change in disclosure of the Statement of Cash Flows.

##### 1.1.1 New standards, amendments and interpretations effective in 2021 and relevant to the Scheme:

Title	Effective date - financial year commencing on or after
<b>Amendments to IFRS 9 'Financial Instruments', IAS 39 'Financial Instruments: Recognition and Measurement', IFRS 7 'Financial Instruments: Disclosures' and IFRS 4 'Insurance Contracts'</b> - The Phase 2 amendments address issues that arise from the implementation of the reform of an interest rate benchmark, including the replacement of one benchmark with an alternative one. This amendment has not had a material impact on the financial statements.	1 January 2021

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 1. PRINCIPAL ACCOUNTING POLICIES (continued)

##### 1.1 Basis of preparation (continued)

##### 1.1.2 New standards, amendments and interpretations not yet effective in 2021 and relevant to the Scheme:

Title	Effective date - financial year commencing on or after
<b>Amendment to IAS 1 'Presentation of Financial Statements' on Classification of Liabilities as Current or Non-current</b> - The amendment clarifies that liabilities are classified as either current or non-current, depending on the rights that exist at the end of the reporting period. Classification is unaffected by expectations of the entity or events after the reporting date.	1 January 2022
<b>IFRS 17 - Insurance contracts</b> - The Standard was issued in May 2017 and supersedes IFRS 4 Insurance Contracts. The Standard creates one accounting model for all insurance contracts and establishes principles for the recognition, measurement, presentation and disclosure of insurance contracts issued. The Standard requires insurance contracts to be measured using updated estimates and assumptions that reflect the timing of cash flows and takes into account any uncertainty relating to insurance contracts. The Standard provides for a simplified approach ("premium allocation approach") for the measurement of a group of insurance contracts only if, at the inception of the group, the entity reasonably expects that the simplification will produce measurement of the liability for remaining coverage that would not differ materially from that produced using the general measurement model and if the coverage period is one year or less. Potential impact: The Scheme has assessed the requirements of the standard and agreed a project plan to implement the standard. The coverage period for the Scheme's contracts is one year or less allowing for the premium allocation approach to be applied, resulting in similar treatment to the current accounting. The most notable exceptions relate to the treatment of onerous contracts and changes to disclosures in the financial statements.	1 January 2023



## **MALCOR MEDICAL AID SCHEME**

### **NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

#### **1. PRINCIPAL ACCOUNTING POLICIES (continued)**

##### **1.2 Classification, recognition, presentation and derecognition of financial instruments**

The Scheme recognises a financial instrument when, and only when, it becomes a party to the contractual provisions of the instrument. The Scheme classifies its financial instruments into the following categories: financial assets or financial liabilities at fair value through profit or loss, and loans and receivables. Loans and receivables are receivables other than those arising from insurance contracts and include sundry accounts receivable and interest receivable. Loans and receivables are disclosed under trade and other receivables.

The classification depends on the purpose for which the financial instruments are acquired. Management determines the classification of financial instruments at initial recognition. All purchases and sales of financial instruments are recognised on the trade date, which is the date on which the Scheme commits to purchase the financial asset or assume financial liability.

##### *Offset*

Where a legally enforceable right of offset exists for recognised financial assets and financial liabilities, and there is an intention to settle the liability and realise the asset simultaneously, or to settle on a net basis, all related financial assets and liabilities are offset.

##### *Derecognition*

Financial assets are derecognised when the rights to receive cash flows from them have expired or where they have been realised, and the Scheme has also transferred substantially all risks and rewards of ownership. The Scheme derecognises a financial liability when the contracted obligation is discharged or expires.

##### **1.3 Financial assets**

##### *Investments at fair value through profit or loss*

The Scheme recognises a financial asset at fair value through profit or loss when upon initial recognition the Scheme designated the asset as fair value through profit or loss. A group of financial assets is designated as at fair value through profit or loss if it is managed and its performance is evaluated on a fair value basis, in accordance with the Scheme's documented risk management strategy, and information about the group of assets is provided internally on that basis to the Scheme's key management personnel. Financial assets at fair value through profit or loss are initially recognised at fair value and the transaction costs are expensed in the profit or loss section of the Statement of Comprehensive Income. The fair value of the financial instruments traded in an active market is determined by using quoted market prices or dealer quotes. Gains or losses arising from subsequent changes in fair value are recognised under Other Income in the Statement of Comprehensive Income within the period in which they arise.

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 1. PRINCIPAL ACCOUNTING POLICIES (continued)

##### 1.3 Financial assets (continued)

###### *Trade and other receivables*

Receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market, other than those the Scheme intends to sell in the short term. Receivables are initially recognised at fair value plus transaction costs. The Scheme holds its Insurance Receivables and Loans and Receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method, less provision for impairment. Trade and other receivables comprise Insurance Receivables, arising from the Scheme's insurance contracts with its members and Loans and Receivables. As part of the implementation of IFRS 9: Financial Instruments, the classification between Insurance Receivables and Loans and Receivables was reassessed. Based on the reassessment, the balance relating to Forensic receivables, previously classified as Loans and Receivables as part of Sundry accounts receivables were reclassified to Insurance Receivables.

###### *Cash and cash equivalents*

Cash and cash equivalents comprise cash on hand, deposits held at call with banks, other short-term liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value, and bank overdrafts. Cash and cash equivalents are carried at fair value.

##### 1.4 Impairment of financial assets

###### *Financial assets carried at amortised cost*

The Scheme assesses at each reporting date, whether there is objective evidence that a financial asset is impaired. A financial asset, or group of financial assets, is impaired and impairment losses are incurred if, and only if, there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a "loss event") and that loss event (or events) has an adverse impact on the estimated future cash flows of the financial asset that can be reliably estimated.

The Scheme first assesses whether objective evidence of impairment exists individually for financial assets such as service provider debtors. In the case of assets which are not individually significant, such as contribution debtors, financial assets are grouped on the basis of similar credit characteristics, such as asset type and past-due status. These characteristics are used in the estimation of future cash flows.

If there is objective evidence that an impairment loss on a financial asset has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows discounted at the financial asset's original effective interest rate. The carrying amount of the asset is reduced and the amount of the loss is recognised in surplus or deficit.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed by adjusting the allowance account. The amount of the reversal is recognised in surplus or deficit.

## **MALCOR MEDICAL AID SCHEME**

### **NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

#### **1. PRINCIPAL ACCOUNTING POLICIES (continued)**

##### **1.4 Impairment of financial assets (continued)**

###### *Impairment of loans and receivables*

Prior to the implementation of IFRS 9, the Scheme applied an incurred loss model to assess impairment of Loans and Receivables. Following the implementation of IFRS 9, the Scheme applies the IFRS 9 simplified approach to measure expected credit losses which uses a lifetime expected loss allowance for Loans and Receivables. To measure the expected credit losses, Loans and Receivables are grouped based on shared credit risk characteristics and days past due. For the year under review the Scheme does not expect any credit losses on these balances and no provision has been made.

##### **1.5 Financial liabilities**

###### *Financial liabilities*

Financial liabilities are initially measured at fair value, and are subsequently measured at amortised cost, using the effective interest rate method.

###### *Insurance payables*

Insurance payables are measured initially at fair value and subsequently measured at amortised cost, using the effective interest rate method.

###### *Trade and other payables*

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers.

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 1. PRINCIPAL ACCOUNTING POLICIES (continued)

##### 1.6 Provisions

Provisions are recognised when the Scheme has a present legal or constructive obligation as a result of past events, for which it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. Where the effect of discounting to present value is material, provisions are adjusted to reflect the time value of money.

##### *Outstanding risk claims provision*

The outstanding risk claims provision comprises a provision made for the estimated ultimate cost of settling all claims incurred but not yet reported at statement of financial position date. Outstanding risk claims are determined as accurately as possible based on a number of factors, which include previous experience in claims patterns, claims settlement patterns, changes in the nature and the number of members according to gender and age, trends in claims frequency, changes in the claims processing cycle, and variations in the nature and average cost incurred per claim.

The Scheme does not discount its provision for outstanding risk claims, as the effect of the time value of money is not considered material.

##### 1.7 Risk contribution income

Contributions are received monthly in advance.

Contributions on member insurance contracts are accounted for monthly when their collection in terms of the insurance contract is reasonably certain. The earned portion of risk contributions received is recognised as revenue. Risk contributions are earned from the date of attached risk, over the indemnity period on a straight line basis. Risk contributions are shown before the deduction of broker service fees and other acquisition costs.

##### 1.8 Relevant healthcare expenditure

Relevant healthcare expenditure consists of net claims incurred, net income/(expense) on risk transfer arrangements and managed care: management services.

##### *Risk claims incurred*

Risk claims incurred comprise the total estimated cost of all claims arising from healthcare events that have occurred in the year and for which the Scheme is responsible, whether or not reported by the end of year.

Risk claims incurred comprise the total of:

- claims submitted and accrued for services rendered during the year, net of recoveries from members for co-payments; and
- claims for services rendered during the previous year not included in the outstanding claims provision for that year, net of recoveries from members for co-payments.

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 1. PRINCIPAL ACCOUNTING POLICIES (continued)

##### 1.8 Relevant healthcare expenditure (continued)

###### *Net income on risk transfer arrangements*

Contracts entered into by the Scheme with third party service providers under which the Scheme is compensated for losses/claims (through the provision of services to members) on contracts that meet the classification requirements of insurance contracts are classified as risk transfer arrangements (reinsurance contracts). Risk transfer arrangements do not reduce the Scheme's primary obligations to its members, but are entered into to decrease the cost the Scheme may incur as a result of the carrying on of the business of a medical scheme.

Only contracts that give rise to a significant transfer of insurance risk are accounted for as risk transfer arrangements. Amounts recoverable under such contracts are recognised in the same year as the related claim.

Risk transfer premiums are recognised as an expense over the indemnity period on the straight line basis. If applicable, a portion of the risk transfer premiums are treated as a prepayment.

Risk transfer recoveries are presented in the statement of comprehensive income on a gross basis. They are calculated on the basis of what it would have cost the scheme had the arrangement been on a fee-for-service basis.

Claims paid in terms of the risk transfer arrangements are calculated based on estimated utilisation statistics.

###### *Managed care: management services*

Managed care: management services expenses comprise amounts paid or payable to a third party for managing the utilisation, costs and quality of healthcare services to the members of the Scheme. These are expensed as incurred.

##### 1.9 Investment income

Investment income comprises interest and dividends on listed instruments, interest on money market instruments and current accounts and net gains or losses on investments at fair value through profit or loss.

Interest is recognised on a yield to maturity basis, taking account of the principal amount outstanding and the effective rate over the period to maturity, when it is determined that such income will accrue to the Scheme.

Dividends and interest are recognised when the right to receive payment is established.

## **MALCOR MEDICAL AID SCHEME**

### **NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

#### **1. PRINCIPAL ACCOUNTING POLICIES (continued)**

##### **1.10 Liabilities and related assets under the liability adequacy test**

Liability adequacy tests are performed to ensure the adequacy of the member insurance contract liabilities as at the statement of financial position date.

The liability for insurance contracts is tested for adequacy by comparing current best estimates of future contractual cash flows with the carrying value of the liability net of any related assets. Where a shortfall is identified, an additional provision is made and charged to the statement of comprehensive income.

##### **1.11 Impairment losses**

The carrying amounts of the Scheme's assets are reviewed at each statement of financial position date to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is estimated.

An impairment loss is recognised whenever the carrying amount of an asset exceeds its recoverable amount. Impairment losses are recognised in the statement of comprehensive income.

###### *Calculation of recoverable amount*

The Scheme's receivables are not discounted to the present value of their estimated future cash flows due to the short term nature of their recoverability.

###### *Reversal of impairment*

An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

##### **1.12 Medical insurance contracts**

Contracts under which the Scheme accepts significant medical insurance risk from another party (the member) by agreeing to compensate the member if a specified uncertain future event (the insured event) adversely affects the member are classified as medical insurance contracts. The contracts issued compensate the Scheme's members for healthcare expenses incurred.

##### **1.13 Broker fees**

Brokers' fees are recognised as incurred.

## **MALCOR MEDICAL AID SCHEME**

### **NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

#### **1. PRINCIPAL ACCOUNTING POLICIES (continued)**

##### **1.14 Reimbursements from the Road Accident Fund**

The Scheme grants assistance to its members in defraying expenditure incurred in connection with rendering of any relevant health service. Such expenditure may be in connection with a claim that is also made to the Road Accident Fund (RAF), administered in terms of the Road Accident Fund Act No. 56 of 1996. If the member is reimbursed by the RAF they are obliged contractually to cede that payment to the Scheme to the extent that they have already been compensated.

Due to the uncertainty around the confirmation and value of the RAF amounts, the Scheme accounts for these amounts on a cash basis and recognises them as third party claim recoveries as a reduction of net claims incurred. Recoveries from the RAF are reflected in third party claim recoveries in the Statement of Comprehensive Income in the current year keeping in mind that some of these recoveries may pertain to prior year claims. The contingent assets are assessed continually to ensure any developments are appropriately reflected in the annual financial statements.

##### **1.15 Allocation of income and expenditure to benefit options**

All allocations between benefit options are based on the actual income and expenditure per benefit option with the exception of:

- Administration expenditure - allocated on membership per benefit option;
- Investment income and asset management fees - allocated pro-rata to risk contribution income per benefit option;
- Managed care: management services - allocated on membership per benefit option;
- The additional funding component

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

	2021 R'000	2020 R'000
<b>2. INVESTMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS</b>		
Cost at the beginning of the year	49,173	48,657
Loss on adjustments to fair value	(2,682)	(1,244)
Fair value at the beginning of the year	46,491	47,413
Additions	100,219	2,022
Acquisitions	99,872	-
Reinvestment of investment income (Note 12)	347	2,022
Disposals	(47,972)	(262)
Disposals at cost	(45,555)	(293)
Realised (losses)/ gains on sale of investment (Note 12)	(2,417)	31
Gain/ (loss) on adjustments to fair value	11,237	(2,682)
<b>Fair value at the end of the year</b>	<b>109,975</b>	<b>46,491</b>
The investments included above represent investments in:		
Listed instruments	-	3,322
Cash on hand and on deposit	-	1,014
Linked insurance policies	109,975	18,163
Unit linked instruments	-	9,804
Money market instruments	-	14,188
<b>Fair value at the end of the year</b>	<b>109,975</b>	<b>46,491</b>
The investments were managed by the following asset managers at year-end:		
Sanlam Private Wealth (Pty) Ltd	-	4,336
Allan Gray Life (Pty)Ltd	-	18,163
Investec Wealth and Investment (Pty) Ltd	-	14,188
Satrix Managers (RF) (Pty) Ltd	-	9,804
Sygnia Asset Management (Pty) Ltd	109,975	-
	<b>109,975</b>	<b>46,491</b>
The investments are non-current and have no fixed maturity date. The fair values of the listed instruments are based on listed market prices and the unit price at the statement of financial position date.		
Investments at fair value through profit or loss are classified as non-current assets, unless they are expected to be realised within twelve months of the statement of financial position date or unless they may need to be sold to raise operating capital.		
The weighted average return for the year on investments at fair value through profit or loss was 6.7% (2020: -4.82%). The weighted average interest rate for the year on money market instruments was 3.97% (2020: 5.38%)		
The asset management fees for the year comprised:		
• Listed instrument management fees	518	231
• Investment advisor fees	33	84
	<b>551</b>	<b>315</b>



## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

	2021 R'000	2020 R'000
<b>3. TRADE AND OTHER RECEIVABLES</b>		
<b>Insurance receivables</b>		
Contributions outstanding	8	77
Member receivables	105	117
Service provider receivables	608	667
	<u>721</u>	<u>861</u>
Less: Provision for impairment losses	(460)	(598)
Forensic debtors	143	242
	<u>404</u>	<u>505</u>
<b>Financial receivables</b>		
Interest receivable	229	389
	<u>229</u>	<u>389</u>
<b>Total trade and other receivables</b>	<b><u>633</u></b>	<b><u>894</u></b>
<p>The carrying amounts of trade and other receivables approximate their fair values due to the short term maturities of these assets.</p>		
<b>Reconciliation of impairment losses</b>		
Members' and service providers' portions that are not recoverable		
Balance at the beginning of the year	598	659
Amount recognised in the statement of comprehensive income for the year	(139)	(61)
Provisions made during the year	141	133
Over provisions reversed during the year	(280)	(194)
Balance at end of the year	<b><u>459</u></b>	<b><u>598</u></b>

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

	2021 R'000	2020 R'000
<b>4. CASH AND CASH EQUIVALENTS</b>		
Current accounts	17,127	17,968
Short term cash deposits	45,211	87,915
	<u>62,338</u>	<u>105,883</u>
<p>The weighted average interest rate for the year on current accounts was 3.29% (2020: 4.10%).</p> <p>The weighted average interest rate for the year on short term cash deposits was 4.12% (2020: 5.37%).</p>		
<b>5. OUTSTANDING RISK CLAIMS PROVISION</b>		
<b>Outstanding risk claims provision</b>	<u>5,750</u>	<u>6,100</u>
<i>Analysis of movement in outstanding risk claims provision</i>		
Balance at beginning of year	6,100	6,900
Payments in respect of prior year	(5,534)	(6,916)
Over/ (under) provision in respect of prior year (Note 8)	566	(16)
Adjustment for the current year (Note 8)	5,184	6,116
<b>Outstanding risk claims provision</b>	<u>5,750</u>	<u>6,100</u>

There is no provision for outstanding claims covered by risk transfer arrangements as this is not considered to be material to the Scheme.

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 5. OUTSTANDING RISK CLAIMS PROVISION (continued)

##### Process used to determine the assumptions

In order to qualify for benefits any claim must, unless otherwise arranged, be submitted to the Scheme not later than the last day of the fourth month following the month in which the healthcare service was rendered.

Each notified claim is assessed on a separate, case by case basis with due regard to the claim circumstances, information available from managed care management services and historical evidence of the size of similar claims. The provisions are based on information currently available. However, the ultimate liabilities may vary as a result of subsequent developments. The percentage of the estimated gross claims paid in 2022 in respect of the 2021 financial year by 31 March 2022 (2020: 31 March 2021) was 90.93% (2020: 88.97%).

The cost of outstanding claims is estimated as follows:

- actual claims notified and assessed during the three months succeeding the financial year end of the Scheme;
- an estimate of claims, using claims information, for the fourth and subsequent months succeeding the financial year end of the Scheme. Historical claims development information is used on the assumption that this pattern will occur again in the future and;
- In addition to normal claims, the Scheme should also raise a provision for State COVID-19 vaccinations that were incurred until 31 December 2021. The Department of Health only started submitting claims for vaccinations carried out at the state facilities to medical schemes from December 2021.

There are reasons why this may not be the case, which, insofar as they can be identified, have been allowed for by modifying the method. Such reasons include:

- changes in the processes that affect the development/recording of claims paid and incurred (such as changes in claims reversing procedures);
- economic, legal, political and social trends (resulting in different than expected levels of inflation and/or minimum medical benefits to be provided);
- changes in composition of memberships; and
- random fluctuations, including the impact of large losses.

The trustees believe that the liability for claims reported in the statement of financial position is adequate and no additional provision is required in terms of a liability adequacy test.

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 5. OUTSTANDING RISK CLAIMS PROVISION (continued)

##### Changes in assumptions and sensitivities to changes in key variables

The table below outlines the sensitivity of insured liability estimates to particular movements in assumptions used in the estimation process. It should be noted that this is a deterministic approach with no correlations between the key variables. Where variables are considered to be immaterial, no impact has been assessed for insignificant changes to these variables. Particular variables may not be considered material at present. However, should the materiality level of an individual variable change, assessment of changes to that variable in the future may be required.

An analysis of sensitivity around various scenarios for the general medical insurance business provides an indication of the adequacy of the estimation process. The Trustees believe that the liability for risk claims reported in the statement of financial position is adequate. However, they recognise that the process of estimation is based upon certain variables and assumptions which could differ when claims arise. Consequently if, for example, the estimate of the unrecorded portion of risk claims for the year was 5% under- or overstated, the impact on the net surplus of the Scheme would be as follows:

Impact on reported surplus due to changes in key variables:

	<b>Change in variables</b>	<b>Variation in claims cost 2021 R'000</b>	<b>Variation in claims costs 2020 R'000</b>
Hospitalisation	5%	91	126
Chronic medication	5%	10	14
Day-to-day benefits	5%	99	132

This analysis has been prepared for a variation in claims run-off factors with other variables remaining constant. An increase or decrease in the provision will result in an increase or decrease in the surplus as follows:

	<b>2021 R'000</b>	<b>2020 R'000</b>
<b>Increase in claims</b>		
Increase in outstanding risk claims provision	(200)	(272)
Decrease in net comprehensive income	200	272
<b>Decrease in claims</b>		
Decrease in outstanding risk claims provision	200	272
Increase in net comprehensive income	(200)	(272)

The sensitivity of the estimation process is reduced by the value of the risk claims paid subsequent to the year end relating to the period ended 31 December 2021.



## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

	2021 R'000	2020 R'000
<b>7. RISK CLAIMS INCURRED</b>		
Current year claims	270,531	246,838
Claims not covered by risk transfer arrangement	267,550	244,434
Claims covered by risk transfer arrangement	2,981	2,404
Movement in outstanding risk claims provision (Note 5)	5,750	6,100
Under provision in respect of prior year	566	(816)
Adjustment for current year	5,184	6,916
<b>Risk claims incurred</b>	<b>276,281</b>	<b>252,938</b>
<b>8. NET INCOME/ (EXPENSE) ON RISK TRANSFER ARRANGEMENTS</b>		
National HealthCare Group (Pty) Ltd		
Risk transfer arrangement fees paid	2,901	2,529
Recoveries under risk transfer arrangement	(2,981)	(2,404)
<b>Net loss (income) on risk transfer arrangement</b>	<b>(80)</b>	<b>125</b>
<p>The Scheme has a capitation agreement with National HealthCare Group (Pty) Ltd. National HealthCare Group (Pty) Ltd bears the cost for all related individual claims less than R600,000 (2020: R600,000) for members on Plan D through their network of suppliers. Should National HealthCare Group (Pty) Ltd default on payment of these claims, the Scheme will be held liable for the cost.</p>		
<b>9. MANAGED CARE: MANAGEMENT SERVICES</b>		
Disease management services	1,901	1,924
Hospital management services	1,918	1,947
Pharmaceutical benefit management services	600	609
Provider network management services	1,619	1,643
	<b>6,038</b>	<b>6,123</b>
Services provided by:		
Discovery Health (Pty) Ltd	6,000	6,085
Isimo Health (Pty) Ltd	38	38
	<b>6,038</b>	<b>6,123</b>

**MALCOR MEDICAL AID SCHEME**

**NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

	<b>2021</b>	<b>2020</b>
	<b>R'000</b>	<b>R'000</b>
<b>10. ADMINISTRATION FEES</b>		
<b>Accredited services</b>		
Customer services	3,808	3,862
Information management and data control	2,699	2,727
Claims management	974	988
Member record management	1,480	1,497
Contribution management	1,300	1,315
Financial management	39	40
<b>Other services</b>		
Forensic investigations and recoveries	395	401
Internal audit services	163	164
Actuarial services	149	151
Governance and compliance	32	32
<b>Additional services</b>		
Quality Management and Monitoring Services	154	155
Advanced Data Analytics	124	126
Digital Service Offering	46	46
Product Innovation	30	30
Enhanced Service Offering	25	26
Enterprise risk management services	25	25
Legal Services	7	7
	<b>11,450</b>	<b>11,594</b>
<b>11. OTHER ADMINISTRATION EXPENSES</b>		
Audit fees	414	419
Audit services - current year	414	397
Audit services - under provision prior year	-	22
Audit committee chairman fees	45	57
Bank charges	108	117
Advisory fees	1,858	1,843
Council for Medical Schemes levies	200	188
Other administration expenses	58	56
Principal officers' fees	678	697
Professional indemnity insurance	46	44
Trustee remuneration	96	95
Trustee reimbursements - travel costs	-	3
	<b>3,503</b>	<b>3,521</b>

**MALCOR MEDICAL AID SCHEME****NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

	2021 R'000	2020 R'000
<b>12. NET IMPAIRMENT LOSSES</b>		
<b>Insurance receivables</b>		
Members' and service providers' portions that are not recoverable	(64)	5
Movement in provision	139	61
Recoveries	(203)	(56)
	<b>(64)</b>	<b>5</b>
<b>13. INVESTMENT INCOME</b>		
<b>Scheme</b>		
Income from available-for-sale investments reinvested (Note 2)	2,134	5,273
Interest income	2,042	4,090
Money market instruments	1,787	3,251
Listed instruments	255	839
Dividend income	92	1,183
Realised gains /(losses) on sale of investments	2,417	(31)
Fair value adjustment on investments at fair value through profit or loss	11,237	(2,682)
Interest on cash and cash equivalents	579	724
	<b>16,367</b>	<b>3,284</b>



**MALCOR MEDICAL AID SCHEME**

**NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

**14. (DEFICIT)/SURPLUS PER BENEFIT OPTION**

2021	Notes	PLAN A R'000	PLAN B R'000	PLAN C R'000	PLAN D R'000	TOTAL R'000
Risk contribution income		69,491	198,770	25,540	3,271	297,072
Relevant healthcare expenditure		(76,341)	(184,003)	(18,064)	(2,901)	(281,310)
Net claims incurred	8	(75,380)	(179,762)	(17,229)	(2,981)	(275,352)
Risk claims incurred		(75,637)	(180,376)	(17,287)	(2,981)	(276,281)
Third party claim recoveries		257	613	59	-	929
Net income on risk transfer arrangements	9	-	-	-	80	80
Risk transfer arrangement fees paid		-	-	-	(2,901)	(2,901)
Recoveries from risk transfer arrangements		-	-	-	2,981	2,981
Managed care: management services	10	(961)	(4,241)	(836)	-	(6,038)
<b>Gross healthcare result</b>		<b>(6,850)</b>	<b>14,766</b>	<b>7,475</b>	<b>371</b>	<b>15,762</b>
Administration fees	10	(1,784)	(7,886)	(1,554)	(227)	(11,450)
Other administration expenses	11	(557)	(2,461)	(485)	-	(3,503)
Broker fees		(225)	(494)	(53)	(24)	(796)
Net impairment losses	12	21	(104)	19	-	(64)
<b>Net healthcare result</b>		<b>(9,394)</b>	<b>3,821</b>	<b>5,402</b>	<b>119</b>	<b>(51)</b>
Other income		5,943	14,381	1,408	181	21,912
Investment income	13	3,828	10,950	1,408	181	16,367
Employer group reinsurance recoveries		2,115	3,404	-	-	5,519
Sundry income		-	26	-	-	26
Asset management fees		(122)	(384)	(45)	-	(551)
<b>Net (deficit)/surplus for the year</b>		<b>(3,573)</b>	<b>17,818</b>	<b>6,764</b>	<b>300</b>	<b>21,310</b>
Number of members at year-end		669	3,000	599	139	4,407

Refer to note 1.14 for basis of allocation of certain income and expenses to Plan options

**MALCOR MEDICAL AID SCHEME**

**NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

**14. (DEFICIT)/SURPLUS PER BENEFIT OPTION (continued)**

2020	Notes	PLAN A R'000	PLAN B R'000	PLAN C R'000	PLAN D R'000	TOTAL R'000
Risk contribution income		73,745	199,395	23,931	2,895	299,966
Relevant healthcare expenditure		(77,840)	(164,471)	(13,517)	(2,529)	(258,356)
Net claims incurred	8	(76,815)	(160,155)	(12,735)	(2,404)	(252,108)
Risk claims incurred		(77,070)	(160,687)	(12,777)	(2,404)	(252,938)
Third party claim recoveries		255	532	42	-	830
Net income on risk transfer arrangements	9	-	-	-	(125)	(125)
Risk transfer arrangement fees paid		-	-	-	(2,529)	(2,529)
Recoveries from risk transfer arrangements		-	-	-	2,404	2,404
Managed care: management services	10	(1,025)	(4,316)	(782)	-	(6,123)
Gross healthcare result		(4,095)	34,924	10,414	366	41,610
Administration fees	10	(1,907)	(8,020)	(1,454)	(211)	(11,592)
Other administration expenses	11	(589)	(2,483)	(449)	-	(3,521)
Broker fees		(181)	(398)	(43)	(19)	(641)
Net impairment losses	12	10	(13)	8	-	5
Net healthcare result		(6,762)	24,010	8,476	136	25,861
Other income		4,349	8,005	289	33	12,676
Investment income	13	785	2,176	289	33	3,284
Employer group reinsurance recoveries		3,564	5,826	-	-	9,389
Sundry income		-	3	-	-	3
Asset management fees		(57)	(239)	(19)	-	(315)
Net (deficit)/surplus for the year		(2,471)	31,776	8,747	169	38,222
Number of members at year-end		723	3,085	589	134	4,531

Refer to note 1.14 for basis of allocation of certain income and expenses to Plan options

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 15. RELATED PARTY TRANSACTIONS

The administrator and advisors of the Scheme are involved in organisations which provide contractual services to the industry including the Scheme and its members.

##### Key management personnel

Key management personnel are those persons having authority and responsibility for planning, directing, controlling and advising on the activities of the Scheme. Key management personnel comprise the board of trustees, principal officer and advisors and those providing administrative services to the Scheme. The administrator and advisor and their family members did not receive any preferential treatment from the Scheme or its administrator.

	2021 R'000	2020 R'000
<b>Transactions with key management personnel</b>		
Statement of comprehensive income transactions		
Principal officers' fees	678	697
Principal officer and trustees:		
- Risk contributions received	879	862
- Risk claims incurred	621	806
Trustee remuneration	96	95
Trustee reimbursements	-	3

The terms and conditions of the above related party transactions were as follows:

Transactions	Nature of transactions and their terms and conditions
Risk contributions received	This constitutes risk contributions paid by the related parties as members of the Scheme. All contributions were on the same terms as applicable to other members.
Risk claims incurred	This constitutes risk claims incurred by the related parties as members of the Scheme. All claims were paid out in terms of the rules of the Scheme.

	2021 R'000	2020 R'000
<b>Discovery Health Proprietary Limited</b>		
Statement of comprehensive income transactions		
Administration fees	11,450	11,594
Managed care: management fees	6,000	6,085
Statement of financial position		
Balance due at year end	1,444	1,423

Discovery Health (Pty) Ltd provides administration and managed care services to the Scheme. Discovery Health (Pty) Ltd has significant influence over the Scheme and it participates in the Scheme's financial and operating policy decisions but does not control the Scheme.

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 15. RELATED PARTY TRANSACTIONS (continued)

Transactions with related parties (continued)	2021 R'000	2020 R'000
<b>Discovery Third Party Recovery Services Proprietary Limited</b>		
Statement of comprehensive income transactions		
Road Accident Fund recoveries	727	367
The Scheme has contracted Discovery Third Party Recovery Services Proprietary Limited (DTPRS), a wholly owned subsidiary of Discovery Health Proprietary Limited, to manage the identification and collection of third party recoveries from the Road Accident Fund.		
<b>Total Medical Aid Administrators Proprietary Limited</b>		
Statement of comprehensive income transactions		
Advisory fees	1,858	1,843
Statement of financial position		
Balance due at year end	152	452
<b>National HealthCare Group Proprietary Limited</b>		
Statement of comprehensive income transactions		
Risk transfer arrangement fees paid	2,901	2,529
<b>Employer Groups</b>		
Statement of comprehensive income transactions		
Reinsurance recoveries	5,519	9,389

The administration and managed care management service agreements are in terms of the rules of the Scheme and in accordance with instructions given by the Board of Trustees. The agreements are automatically renewed each year unless notification of termination is received or following the cancellation of the Administrator's accreditation or the issue of a lawful directive to this effect by the Council for Medical Schemes in terms of the Medical Schemes Act, No 131 of 1998, as amended. The Scheme and the Administrator/Managed Healthcare Organisation shall be entitled to terminate the agreement by giving notice in writing of not less than 90 days and not more than 180 days. The outstanding balances bears no interest and is due within 7 days.

#### 16. FIDELITY AND PROFESSIONAL INDEMNITY COVER

In terms of section 33(3) of the Medical Schemes Act, Camargue Underwriting Managers Proprietary Limited, underwritten by Bryte Insurance Company Ltd, Compass Insurance Company Ltd and Lloyds Bank Of London Ltd, has provided professional indemnity and fidelity insurance of R25 million (2020: R25 million) to the Scheme.

The staff of the administrator were covered against fidelity claims through their employer indemnity insurance.

#### 17. CRITICAL ACCOUNTING JUDGEMENTS AND AREAS OF KEY SOURCES OF ESTIMATION UNCERTAINTY

In the process of applying the Scheme's accounting policies, the trustees are required to make critical assumptions regarding the future and accounting judgements. In the current and prior year the most significant estimates were considered to be the determination of:

- The outstanding risk claims provision (Refer note 5 to the financial statements); and
- The provision for impairment losses (Refer note 3 to the financial statements).

In the opinion of the Board of Trustees, these estimates and assumptions are not likely to create a significant risk of a material adjustment to the carrying values of assets and liabilities during the next financial year.

## **MALCOR MEDICAL AID SCHEME**

### **NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

#### **18. INSURANCE RISK MANAGEMENT**

##### **Risk management objectives and policies for mitigating medical insurance risk**

The primary medical activity carried out by the Scheme assumes the risk of loss from members and their dependants who are directly subject to medical insurance risk. These risks relate to the health of the Scheme members. As such the Scheme is exposed to the uncertainty surrounding the timing, severity of claims, changing epidemiology, and unexpected catastrophic events under each contract. The Scheme also has exposure to market risk such as changing member profiles and investment activities.

The Scheme uses several methods to assess and monitor medical insurance risk exposures both for individual types of risks insured and overall risks. The principal risk is that the frequency and severity of claims is greater than expected. Insurance events are, by their nature, random and the actual number and size of events during any one year may vary from those estimated using established statistical techniques.

Chronic medicine benefits cover the cost of medicines for conditions listed in the Chronic Disease List such as high blood pressure, cholesterol and asthma, as well as prescribed medicines for other specified conditions which are categorised as chronic, and are paid according to accepted protocols, and may be subject to limits.

As a result of regulations under the Medical Schemes Act, medical schemes are required to provide Prescribed Minimum Benefits, and the Scheme makes every effort to be compliant with this requirement. Such benefits are provided according to the regulated criteria and protocols.

Day to day benefits cover the cost (up to 100% of the Malcor rate for the appropriate year) of all out of hospital services, such as visits to medical practitioners and dentists, services rendered by auxiliaries and supplementary services, as well as prescribed non-chronic medicines.

Management information, including contribution income and claims ratios per plan is reviewed monthly.

##### **Medical insurance risks facing the Scheme**

The most significant medical insurance risk facing the Scheme is that risk contribution income will not be sufficient to cover risk claims expenditure and non-healthcare costs and will therefore not result in a surplus to enable the Scheme to achieve and maintain the required accumulated funds ratio.

Expected claims are determined on the basis of past claims experience, allowing for the effects of tariff and utilisation increases, and changes in benefit design. Prices are determined and managed according to changes in the National Health Reference Price List ("NHRPL") published by the Department of Health in 2006 and subsequently escalated by medical inflation annually, regulated fees such as dispensing fees, and negotiations with providers in certain major medical expense categories. Contributions are calculated so as to cover those claims, non-healthcare costs, and provide a surplus. There is always the risk that the past claims were overstated or understated, and/or that the calculations could be affected by changes in the membership profile or regulatory requirements, and that the contributions could consequently be calculated on the incorrect basis.

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 18. INSURANCE RISK MANAGEMENT (continued)

##### Medical insurance risks facing the Scheme (continued)

It is necessary, due to regulatory requirements for registering benefits and contributions in advance for the ensuing year, to estimate tariff increases and increases in benefit utilisation before negotiations with certain provider groups can be concluded. The extent of increases in the single exit prices for medicines also have to be estimated. All these factors constitute a risk that the results for the ensuing year will be affected by the use of the incorrect assumptions.

Changes in the membership profile as a result of plan selection, ageing of beneficiaries and demographics pose a risk to the Scheme, due to the effect they could have on claims experience, even though these factors are constantly monitored.

##### Concentration of medical insurance risks

The following table summarises the concentration of insurance risk per beneficiary, with reference to the carrying amount, net of adjustments, of the insurance claims incurred by age group and in relation to the type of risk covered.

Age grouping (in years)	Average claims per beneficiary per year					
	2021			2020		
	Unlimited risk*	Limited risk**	Total	Unlimited risk*	Limited risk**	Total
	R	R	R	R	R	R
< 25	5,913	6,668	12,580	5,215	5,349	10,564
25 - 34	8,900	11,424	20,323	8,738	10,569	19,307
35 - 49	13,054	13,090	26,145	11,209	11,499	22,708
50 - 64	25,844	16,010	41,854	24,270	13,108	37,378
> 65	42,541	18,115	60,656	39,524	15,486	55,010

\* Unlimited risk claims comprise the cost to the Scheme of hospitalisation and related in-hospital treatment, Prescribed Minimum Benefits and chronic conditions for which there are no individual annual claim limits.

\*\* Limited risk claims comprise the cost to the Scheme of all benefits for which there is an individual annual claim limit.

##### Management of forensic risk

The administrator provides a forensic service which analyses claims and investigates possible fraud and abuse of the benefits by providers and members, and institutes appropriate action.

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 18. INSURANCE RISK MANAGEMENT (continued)

##### *Risk transfer arrangements*

For a number of years the employer groups have elected to arrange stop-loss reinsurance cover outside the Scheme for hospital claims in excess of R300,000 per claim. The Scheme therefore has no requirement for reinsurance for its hospital claims. Nevertheless the employer groups have undertaken to contribute any reinsurance claim proceeds that they receive in terms of this cover to the Scheme by way of additional funding.

The Scheme has a capitation agreement with National HealthCare Group (Pty) Ltd which in return for a premium payable per member bears the risk for all individual claims less than R600,000 (2020: R600,000) per member in respect of all members of Plan D.

##### *Sensitivity to insurance risk*

A sensitivity analysis reflecting the impact on the Scheme's reported results for the year is as follows: A 1% movement in either direction in the cost of risk claims incurred with all other variables held constant would have either a negative or positive effect of R2,73 million (2020: R2,53 million) on the Scheme's risk claims incurred and net surplus for the year. The unlimited risk claim portion of this total amounts to R1,48 million (2020: R1,00 million).

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 19. FINANCIAL RISK MANAGEMENT

##### Overview

The Scheme's activities expose it to a variety of financial risks, including the effects of changes in equity market prices, foreign currency exchange rates and interest rates. The Scheme's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potentially adverse effects on the financial performance of the investments, which the Scheme holds to meet its obligations to its members.

Risk management and investment decisions are made by the trustees in consultation with the investment advisor.

##### Financial risk factors

###### *Currency risk*

The Scheme operates in South Africa and therefore its cash flows are denominated in South African Rand.

###### *Interest rate risk*

The investments of the Scheme, both long term and short term, comply with the regulations as set out in Regulation 30, annexure B, of the Medical Schemes Act.

Returns on interest bearing investments vary according to Reserve Bank monetary policy decisions.

The table below summarises the Scheme's exposure to interest rate risk. Included in the table are the Scheme's investments at carrying amounts. The investments that are subject to interest rate risks have been aged by the estimated period in which they could reasonably be liquidated.

	Up to 1 month R'000	1 - 3 months R'000	Greater than 4 months R'000	Non-interest bearing R'000	Total R'000
<b>As at 31 December 2021</b>					
Investments at fair value through profit or loss	109,975	-	-	-	109,975
Cash and cash equivalents	62,338	-	-	-	62,338
	172,313	-	-	-	172,313
<b>As at 31 December 2020</b>					
Investments at fair value through profit or loss	36,687	-	-	9,804	46,491
Cash and cash equivalents	105,883	-	-	-	105,883
	142,570	-	-	9,804	152,374

Non-interest bearing investments comprise investment in equity, commodities, property and preference shares.



**MALCOR MEDICAL AID SCHEME**

**NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

**19. FINANCIAL RISK MANAGEMENT (continued)**

**Financial risk factors (continued)**

*Credit risk*

The Scheme's principal financial assets comprise investments held at fair value through profit or loss, trade and other receivables and cash and cash equivalents. The Scheme's credit risk is primarily attributable to its trade and other receivables. The amounts presented in the statement of financial position are net of allowances for impairment. An allowance for impairment is made where there is an identified loss event which, based on previous experience, is evidence of a reduction in the recoverability of the cash flows. Derivative counterparties (if applicable) and cash transactions are limited to high credit quality financial institutions.

With respect to available-for-sale investments and cash and cash equivalents the Scheme limits its counterparty exposure by only dealing with financial institutions that have high external credit quality ratings. The Scheme has a policy of limiting the amount of credit exposure to any one financial institution in accordance with the limitation on asset requirements specified in the Regulations to the Medical Schemes Act.

Credit risk in respect of trade and other receivables is controlled through the application of credit monitoring procedures. Section 26(7) of the Medical Schemes Act requires all contributions to be paid to the Scheme within 3 days of becoming due. Whilst every effort is made to enforce this requirement the onus is on the member/employer group to ensure compliance. The rules of the Scheme provide for suspension and ultimately termination of membership after specified periods of non-compliance.

*Exposure to credit risk*

	Insurance receivables			
	Contribution receivables		Member and provider claim receivables	
	2021 R'000	2020 R'000	2021 R'000	2020 R'000
Carrying amount	8	77	714	784
Past due but not impaired - carrying amount	-	-	33	103
30 - 60 days	-	-	23	37
61 - 90 days	-	-	7	62
91 days +	-	-	2	3
Collectively impaired - carrying amount	-	-	460	598
Neither past due not impaired	8	77	45	83
	8	77	537	784

*Past due but not impaired*

Contribution and member and provider receivable payments are past due but the Scheme believes that impairment is not appropriate on the basis of the stage of collection of amounts owed to the Scheme.

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 19. FINANCIAL RISK MANAGEMENT REPORT (continued)

##### Financial risk factors (continued)

###### *Collectively impaired/allowance for impairment*

Trade and other receivables are recoverable but, in exceptional circumstances small amounts may be irrecoverable. These irrecoverable amounts are written off as bad debts.

###### *Capital adequacy risk*

The Scheme's objective when managing capital is to safeguard its ability to continue as a going concern in order to provide benefits for its stakeholders.

The principal risk is that the frequency and severity of claims is greater than expected and that there are insufficient reserves to provide for their settlement.

The Medical Schemes Act, 131 of 1998 requires a minimum accumulated funds (solvency) ratio, calculated as accumulated funds expressed as a percentage of registered contributions, of 25%. The Scheme's solvency ratio based on registered contributions was 45.87% (2020: 41.71%) at 31 December 2021.

###### *Liquidity risk*

Prudent liquidity risk management implies maintaining sufficient cash. The availability of funding through liquid holding cash positions with various financial institutions ensures that the Scheme has the ability to fund the day-to-day operations of the Scheme.

The table below summarises the Scheme's financial liabilities analysed by the expected maturity dates.

	Up to 1 month R'000	1 - 3 months R'000	4 - 12 months R'000	Total R'000
<b>As at 31 December 2021</b>				
Outstanding risk claims provision	3,563	2,337	-	5,900
Trade and other payables	20,772	-	-	20,772
	24,335	2,337	-	26,671
<b>As at 31 December 2020</b>				
Outstanding risk claims provision	4,687	1,413	-	6,100
Trade and other payables	21,657	-	397	22,054
	26,344	1,413	397	28,153

###### *Market risk*

Market risk is the risk that changes in market prices such as the interest rate, equity prices, foreign exchange rates and credit spreads will affect the Scheme's investment income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposure within acceptable parameters, while optimising the return on investments.

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 19. FINANCIAL RISK MANAGEMENT (continued)

##### Financial risk factors (continued)

###### *Sensitivity risk*

###### *Listed and unit-linked investments*

A 5% movement in the market value of investments in either direction would have had either a positive or negative effect of R5,499 million (2020: R1,615 million) on the market value of the portfolio at year end.

###### *Fair value estimation*

IFRS 7 requires disclosure of fair value measurements of financial instruments by level in terms of the following fair value measurement hierarchy:

- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (such as derived from prices).
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

##### Investments at fair value through profit or loss

Directly listed instruments  
Unit linked listed instruments  
Money market instruments

2021 R'000	2020 R'000
-	4,336
109,975	27,967
-	14,188
109,975	46,491

The Scheme's investments are all valued on a level 2 basis. For the 2020 financial year the only level 1 investments were the directly listed instruments above.

##### Unconsolidated investment structures

The Scheme invests monies in reputable funds which provide returns to the Scheme. The Scheme's view is that these funds are not unconsolidated structured entities. The Scheme monitors the performance of the funds closely to ensure high earnings without unnecessary exposure to risk. The Scheme's exposure to risk is limited to the fair value of these investments.

**MALCOR MEDICAL AID SCHEME**

**NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

**19. FINANCIAL RISK MANAGEMENT (continued)**

**Breakdown of investments**

The following table analyses the financial assets and financial liabilities of the Scheme per class of assets and liabilities:

	Investments at fair value through profit or loss	Financial assets	Insurance receivables and (payables)	Financial liabilities at amortised cost	Total carrying amount	Fair value amount
	R'000	R'000	R'000	R'000	R'000	R'000
<b>As at 31 December 2021</b>						
Investments						
Held at fair value through profit or loss	109,975	-	-	-	109,975	109,975
Money market instruments	-	-	-	-	-	-
Cash and cash equivalents	-	62,338	-	-	62,338	62,338
Trade and other receivables	-	229	404	-	633	633
Trade and other payables	-	-	(18,759)	(2,013)	(20,772)	(20,772)
	109,975	62,567	(18,355)	(2,013)	152,174	152,174
<b>As at 31 December 2020</b>						
Investments						
Held at fair value through profit or loss	32,303	-	-	-	32,303	32,303
Money market instruments	14,188	-	-	-	14,188	14,188
Cash and cash equivalents	-	105,883	-	-	105,883	105,883
Trade and other receivables	-	389	505	-	894	894
Trade and other payables	-	-	(19,570)	(2,484)	(22,054)	(22,054)
	46,491	106,271	(19,066)	(2,484)	131,214	131,214

## **MALCOR MEDICAL AID SCHEME**

### **NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

## **20. NON COMPLIANCE WITH MEDICAL SCHEME LEGISLATION FOR THE YEAR UNDER REVIEW**

### **20.1 Late payment of contributions**

#### **Nature and impact**

In terms of Section 26(7) of the Act, contributions should be received in accordance with the rules of the Scheme. In terms of the Scheme rules, contributions are required to be received no later than three days after their due date. During the financial year certain contributions were identified that were not paid to the Scheme within this deadline period.

#### **Causes of failure**

The failure was mainly caused due to administrative delays by certain participating employers in paying over their respective contributions to the Scheme.

#### **Corrective action**

Whilst every effort is made through credit control procedures to enforce this requirement, the onus is on the member/employer group to ensure compliance. The loss of interest to the Scheme from this delay is minimal.

### **20.2 Investments in participating employers and medical scheme administrators**

#### **Nature and impact**

Section 35(8)(a), (c) and (d) of the Act states that a medical scheme shall not invest any of its assets in participating employers, medical scheme administrators or persons associated with these organisations. During the year the Scheme did have investments in certain of these organisations.

#### **Causes of failure**

The Scheme invests in investment vehicles which allow investment managers discretion to invest in organisations of their choice. Certain of these choices have resulted in the Scheme having investments in organisations which are in conflict with this Section of the Act.

#### **Corrective action**

The Scheme has received exemption from the provisions of this Section from Council on the grounds that the investments are made, without reference to the Scheme, by the asset managers in the portfolios in which the Scheme invests. These investment choices are therefore not influenced by the Scheme.

## **MALCOR MEDICAL AID SCHEME**

### **NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

#### **20. NON COMPLIANCE WITH MEDICAL SCHEME LEGISLATION FOR THE YEAR UNDER REVIEW (continued)**

##### **20.3 Sustainability of benefit options**

###### **Nature and impact**

In terms of section 33(2) of the Act, each benefit option shall be self-supporting in terms of membership and financial performance. At 31 December 2021 one of the four benefit options incurred deficits as set out in note 14 to the annual financial statements.

###### **Causes of failure**

Plan A was deliberately costed to incur a deficit as the increase in contributions necessary to achieve a surplus would have been too onerous for members on this plan and might lead to members changing to other plans to the detriment of the Scheme as a whole.

###### **Corrective action**

The Trustees are expecting this trend for Plan A to continue in future. The performance of all benefit options is monitored on a continuous basis with a view to improving their financial outcomes, and the Scheme continually evaluates different strategies to address the deficit in these benefit options.

When structuring benefit options, the financial sustainability of all the benefit options is considered. The different financial positions reflect the different disease burdens in each benefit option, among many other factors. The Scheme's strategy on the sustainability of benefit options has to balance short and long-term financial considerations, fairness to both healthy and sick members, and continued affordability of cover for members with different levels of income and healthcare needs. While the Scheme is committed to complying wherever possible with the applicable legislation, it also focuses intensively on the overall stability and financial position of the Scheme as a whole and not only individual benefit options.

In addition, the Scheme continually provides the Registrar with updates on both the Scheme and individual benefit option performance through the monthly management accounts and quarterly monitoring meetings.

## **MALCOR MEDICAL AID SCHEME**

### **NOTES TO THE FINANCIAL STATEMENTS**

for the year ended 31 December 2021

#### **20. NON COMPLIANCE WITH MEDICAL SCHEME LEGISLATION FOR THE YEAR UNDER REVIEW (continued)**

##### **20.4 Late payment of claims**

###### **Nature and impact**

Section 59(2) of the Act requires that medical schemes shall pay a member or a supplier of service, any benefit owing to that member or supplier of service within 30 days after the day on which the claim in respect of such benefit was received by the medical scheme.

###### **Causes of failure**

Late payment of claims usually resulted from members or providers submitted claims without the necessary details for these payments to be made timeously. These are isolated cases and thus do not have a material effect on the Scheme.

###### **Corrective action**

The necessary assistance is provided to the identified members and healthcare providers to ensure that these types of isolated cases are minimised.

#### **21. EVENTS AFTER THE REPORTING DATE**

There were no other events after the reporting date that had a material impact on the Scheme.

#### **22. CONTINGENT ASSETS**

The Scheme has approximately R3 366 105 (2020: R3 384 469) in recoveries outstanding from the Road Accident Fund (RAF) for claims paid on behalf of members. The general likelihood of recovery of these amounts is uncertain, and the Trustees have elected not to recognise a debtor on the statement of financial position as any future recoveries are contingent on a multitude of factors. The Trustees consider, based on past experience and the current financial stability of the RAF, that the debtor, were it to be recognised would be impaired by R3 366 105 (2020: R3 384 469).

## MALCOR MEDICAL AID SCHEME

### NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2021

#### 23. CHANGE IN THE ACCOUNTING POLICY - FORMAT OF THE STATEMENT OF CASH FLOWS

2020 RESTATED	2020 R'000
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>	
Cash receipts from members and providers	301,007
• Cash receipts from members - contributions	299,882
• Cash receipts from members and providers – other	1,125
Cash paid to providers, employees and members	(268,389)
• Cash paid to providers and members – claims	(251,879)
• Cash paid to providers and employees – non-healthcare expenditure	(16,510)
Sundry income	9,392
<b>NET CASH FLOWS FROM OPERATING ACTIVITIES</b>	<b>42,010</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>	
Purchase of investments	(2,022)
Proceeds on disposal of investments held at fair value through profit or loss	262
Investment income	6,697
<b>NET CASH FLOWS FROM INVESTING ACTIVITIES</b>	<b>4,937</b>
<b>NET INCREASE IN CASH AND CASH EQUIVALENTS</b>	<b>46,947</b>
<b>PREVIOUSLY PRESENTED</b>	
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>	
Cash inflow from operations before working capital changes	34,907
Working capital changes	
• Decrease in trade and other receivables	719
• Increase/(Decrease) in outstanding risk claims provision	(800)
• (Decrease)/(Increase) in trade and other payables	7,884
<b>NET CASH FLOWS FROM OPERATING ACTIVITIES</b>	<b>42,710</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>	
Purchase of investments	(2,022)
Proceeds on disposal of investments held at fair value through profit or loss	262
Investment income	5,997
<b>NET CASH FLOWS FROM INVESTING ACTIVITIES</b>	<b>4,237</b>
<b>NET INCREASE IN CASH AND CASH EQUIVALENTS</b>	<b>46,947</b>





Call Centre 0860 100 698 | [service@malcormedicalaid.co.za](mailto:service@malcormedicalaid.co.za) | [www.malcormedicalaid.co.za](http://www.malcormedicalaid.co.za)

---

Malcor Medical Aid Scheme, registration number 1547. Administered by Discovery Health (Pty) Ltd, registration number 1997/013480/07, an authorised financial services provider.